Citation Impact
Citing Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
2005 Standout
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
2006 Standout
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
2009 Standout
Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus
2014 StandoutNobel
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas
2007 Standout
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Intestinal Transport of Irinotecan in Caco-2 Cells and MDCK II Cells Overexpressing Efflux Transporters Pgp, cMOAT, and MRP1
2002
Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins
2005
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients
2000
Mechanisms of Camptothecin Resistance by Human Topoisomerase I Mutations
2004
Nrf2: friend or foe for chemoprevention?
2009
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1
2006
Cancer chemoprevention with dietary phytochemicals
2003 Standout
Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein
1998
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
2008 StandoutNature
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
2006 Standout
HIF-1: upstream and downstream of cancer metabolism
2009 StandoutNobel
Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
2010 Standout
Phase 2 study of weekly irinotecan in adults with recurrent malignantglioma: Final report of NABTT 97-11
2004
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Synthesis of Biomolecule‐Modified Mesoporous Silica Nanoparticles for Targeted Hydrophobic Drug Delivery to Cancer Cells
2011 StandoutNobel
XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer
2009
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma
2003
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
2008 Standout
Stimuli-responsive nanocarriers for drug delivery
2013 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
1997
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
1996
Upstream and downstream of mTOR
2004 Standout
Targeting multidrug resistance in cancer
2006 Standout
Gut microbiota modulation of chemotherapy efficacy and toxicity
2017 Standout
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity
2002
Medical management of patients with brain tumors
2006
Malignant Gliomas in Adults
2008 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Apoptosis
2002 Standout
Genetic Variation of the IL-28B Promoter Affecting Gene Expression
2011
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer
1999
Topoisomerase I inhibitors: Review and update
1997
Role of phase 2 enzyme induction in chemoprotection by dithiolethiones
2001
Defining the Role of mTOR in Cancer
2007 Standout
Camptothecin and Its Analogs
1996
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
2000 Standout
Effects of Dietary Oltipraz and Ethoxyquin on Aflatoxin B1 Biotransformation in Non-Human Primates
2000
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Herb-Drug Interactions
2005 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
2004
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin
2001
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes
2004 StandoutNobel
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
2001
Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants
2002 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Role of Nrf2 in Oxidative Stress and Toxicity
2013 Standout
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
2000
Multispecific Organic Anion Transporter Is Responsible for the Biliary Excretion of the Camptothecin Derivative Irinotecan and its Metabolites in Rats
1997
Molecular Modeling Studies of the DNA−Topoisomerase I Ternary Cleavable Complex with Camptothecin
1998 StandoutNobel
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
1999
Decrease in topoisomerase I is responsible for activation-induced cytidine deaminase (AID)-dependent somatic hypermutation
2011 StandoutNobel
Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
2000
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
2001
Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short).
2001
Polymer-Caged Nanobins for Synergistic Cisplatin−Doxorubicin Combination Chemotherapy
2010
Combination of Oxaliplatin Plus Irinotecan in Patients With Gastrointestinal Tumors: Results of Two Independent Phase I Studies With Pharmacokinetics
1999
The mechanism of topoisomerase I poisoning by a camptothecin analog
2002
Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
1998
Potent Protection against Aflatoxin-Induced Tumorigenesis through Induction of Nrf2-Regulated Pathways by the Triterpenoid 1-[2-Cyano-3-,12-Dioxooleana-1,9(11)-Dien-28-Oyl]Imidazole
2006
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
2008 Standout
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
1996
The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis
2018 Standout
PEGylated Nanographene Oxide for Delivery of Water-Insoluble Cancer Drugs
2008 Standout
Ratiometric delivery of cisplatin and doxorubicin using tumour-targeting carbon-nanotubes entrapping platinum(iv ) prodrugs
2014
Chemoprevention by inducers of carcinogen detoxication enzymes.
1997
Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
2004
Pharmacokinetic Interactions of Drugs with St John’s Wort
2004
Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice
2001
Topoisomerase I inhibitors: selectivity and cellular resistance
1999
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study
2007
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea
2002
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Dysregulation of the TSC-mTOR pathway in human disease
2004 Standout
DNA Topoisomerases: Structure, Function, and Mechanism
2001 Standout
Works of E Gupta being referenced
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
1997
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
1997
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
1996
The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s).
2000
Phase I Clinical and Pharmacologic Study of 13-cis-Retinoic Acid, Interferon Alfa, and Paclitaxel in Patients With Prostate Cancer and Other Advanced Malignancies
1999
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
1994
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
1996
Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.
1995
Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
1997